<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645229</url>
  </required_header>
  <id_info>
    <org_study_id>A1281055</org_study_id>
    <nct_id>NCT00645229</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder</brief_title>
  <official_title>Efficacy And Safety Of Ziprasidone In Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder, Including Patients With A Diagnosis Of Recent Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of ziprasidone in acute
      exacerbation of schizophrenia or schizoaffective disorder, including patients with recent
      onset of symptoms
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was prematurely discontinued due to the difficulty of subject recruitment on March
      24, 2005. There were no safety concerns that led to the decision to terminate.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Please see Detailed Description for termination reason.
  </why_stopped>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in PANSS (Depression-C) score at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Clinical Global Impressions-Severity (CGI-S) total score at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in CGI-S total score at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs and weight at screening, baseline, Day 3, Week 1, and Months 1, 2, 3, 4, 5, and 6</measure>
    <time_frame>Screening, baseline, Day 3, Week 1, and Months 1, 2, 3, 4, 5, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Global Impressions-Improvement (CGI-I) score at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events on Day 3, Week 1, and Months 1, 2, 3, 4, 5, and 6</measure>
    <time_frame>Day 3, Week 1, and Months 1, 2, 3, 4, 5, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Global Assessment of Functioning (GAF) score at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters at screening, baseline, Day 3, Week 1, and Months 1, 2, 3, 4, 5, and 6</measure>
    <time_frame>Screening, baseline, Day 3, Week 1, and Months 1, 2, 3, 4, 5, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simpson-Angus Scale (SAS) at screening, baseline, Day 3, Week 1, and Months 1, 2, 3, 4, 5, and 6</measure>
    <time_frame>Screening, baseline, Day 3, Week 1, and Months 1, 2, 3, 4, 5, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barnes Akathisia Scale (BAS) at screening, baseline, Day 3, Week 1, and Months 1, 2, 3, 4, 5, and 6</measure>
    <time_frame>Screening, baseline, Day 3, Week 1, and Months 1, 2, 3, 4, 5, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Screening and Month 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Geodon, Zeldox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients not currently being treated with antipsychotic medication and neuroleptic
             naive patients

          -  Diagnosis of schizophrenia or schizoaffective disorder

          -  Antipsychotic treatment prior to screening was to be for a cumulative period of less
             than 5 years

        Exclusion Criteria:

          -  Patients at immediate risk of committing harm to self or others

          -  Treatment with clozapine within 3 months prior to baseline

          -  History of neuroleptic treatment

          -  Current antipsychotic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1600-219</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281055&amp;StudyName=A%20study%20of%20the%20efficacy%20and%20safety%20of%20ziprasidone%20in%20patients%20with%20acute%20exacerbation%20of%20schizophrenia%20or%20schizoaffective%20disorder</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2008</study_first_submitted>
  <study_first_submitted_qc>March 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <last_update_submitted>April 7, 2008</last_update_submitted>
  <last_update_submitted_qc>April 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

